Business Wire

1E

11.1.2022 14:12:14 CET | Business Wire | Press release

Share
1E doubles down for massive growth in DEX category with leadership transformation focused on Customer Success, Product, Technology and Sales

1E , the leader in Digital Employee Experience (DEX), today appointed six new senior leaders in response to booming growth in the DEX category as organizations increasingly prioritize supporting the hybrid and remote work needs of employees.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111005732/en/

“2022 is going to be an epic year for 1E. We start the year on the heels of our biggest quarter ever and the launch of the latest generation of our SaaS Digital Employee Experience platform, 1E Tachyon. We've also seen significant tailwinds as DEX has become a major boardroom priority as a way to understand employee engagement, happiness and productivity in uncertain times” said Mark Banfield, CEO of 1E. “These new appointments, half of whom are women, are a key piece of the puzzle in our aggressive growth strategy and will propel us to new heights as we lead the way in writing DEX history.”

Building an organization acutely focused on customer success was paramount to 1E’s business transformation. This new approach puts 1E customers at the center so that they are better equipped to support and improve the digital experience of their employees. 1E is also doubling down on product and technology. These new additions are reflective of this strategy.

New appointments include:

● Marie Palmer, Chief Customer Officer

● Ian Van Reenen, Chief Technology Officer

● Amy Collins, Senior Vice President, Product

● Alice Carlisle, Vice President, Sales for EMEA

● Lucas Ryder, Vice President, Sales for North America

● Jason Keogh, Field CTO

Marie Palmer joins as 1E’s Chief Customer Officer. Marie, who has over fifteen years of experience leading customer success teams, the last six of which were devoted to leading customer success for VMWare in EMEA and APAC.

Ian Van Reenen joins 1E as Chief Technology Officer. Ian, a veteran technologist, has over 20 years’ experience building products to help IT departments offer a more secure, efficient, and better service at companies such as Datto, Autotask and CentraStage.

Amy Collins has been promoted to Senior Vice President, Product. Amy has worked in the technology sector for 20 years and has spent most of this time in product roles building software products in fast growth, disruptive technology companies such as Brandwatch and Signal AI.

Alice Carlisle and Lucas Ryder join as Vice President of Sales for EMEA and North America respectively. Carlisle joins most recently from LogicMonitor, where she achieved significant growth in EMEA sales, and Ryder joins from Darktrace, where he ran sales in North America. Both worked together previously at Autotask and Datto.

Jason Keogh has been promoted to Field CTO to help 1E customers map their DEX requirements back to technology solutions and to build a feedback loop between the customer base and product team. Prior to joining 1E, Jason was founder and CTO of iQuate.

About 1E

1E are the innovators in Digital Employee Experience (DEX) that supports the work from anywhere enterprise, so employees are secure, supported, and productive wherever they want to be. The 1E Tachyon Platform provides real-time diagnosis, remediation and automation that fixes issues, fast and without interruption. It puts employees in control, through self-service, self-heal and sentiment monitoring to understand how they really feel and reduces help desk calls and ultimately costs. That’s why more than 500 organizations in 42 countries trust 1E to help them manage 11 million endpoints seamlessly. For more information, visit www.1E.com .

###

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye